Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5)
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/12240/Sakiin-Abdullah-2024.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Date
2024Author
Şenocak Taşçı, ElifOyan, Başak
Sönmez, Özlem
Mutlu, Arda Ulaş
Atcı, Muhammed Mustafa
Sakin, Abdullah
Öner, İrem
Yeşil Çınkır, Havva
Karakurt Eryılmaz, Melek
Çağlayan, Dilek
Yazdan Balçık, Onur
Paksoy, Nail
Bozkurt, Mustafa
Metadata
Show full item recordCitation
Şenocak Taşçı, E., Oyan, B., Sönmez, Ö., Mutlu, A. U., Atcı, M. M., Sakin, A. ... Bozkurt, M. (2024). Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5). BMC Cancer, 24(1). https://dx.doi.org/10.1186/s12885-024-11863-0Abstract
Following publication of the original article [1], the authors reported an error in the affiliations of authors Başak Oyan, Özlem Sönmez, Leyla Özer, Ali Arıcan, Özlem Er and Mustafa Bozkurt. These authors are all affiliated to institution 2.